Cancer is a global health burden. 44 million people live with cancer and every year 18 million people are diagnosed with cancer. Despite decades of innovation, significant unmet medical needs remain – including early diagnosis and intervention, more effective treatment options, with improved therapies, personalized treatment and combination regimens for optimal outcomes. Often times, balancing efficacy and tolerability is a tradeoff.
At Ascelia Pharma, we develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance (former working name Mangoral) and Oncoral – in clinical development.